<DOC>
	<DOCNO>NCT02339441</DOCNO>
	<brief_summary>The aim study compare effectiveness commonly use immunosuppressant treatment early diffuse cutaneous systemic sclerosis ( SSc ) .</brief_summary>
	<brief_title>Treatment Outcome Early Diffuse Cutaneous Systemic Sclerosis</brief_title>
	<detailed_description>Diffuse cutaneous systemic sclerosis ( SSc ) rare autoimmune disease characterise excessive connective tissue skin ( cause skin thickening call 'scleroderma ' ) , muscle , joint internal organ . A number different drug effect immune system ( know 'immunosuppressants ' ) currently use clinician treatment early diffuse cutaneous SSc , significant side effect . We want know whether one definitely effective , , effective .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age &gt; 18 Skin thicken &lt; 3 year Immunosuppressant use &lt; 4 month Proximal skin involvement face/neck , elbow knee Previous use 4 month methotrexate , mycophenolate mofetil , cyclophosphamide immunosuppressive treatment Previous use immunosuppressant therapy methotrexate , mycophenolate mofetil cyclophosphamide within previous month Previous stem cell transplantation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Systemic sclerosis</keyword>
</DOC>